A five-year follow-up of the verbal memory performance of individuals with bipolar disorder and schizophrenia: evidence of unchanging deficits under treatment

Czepielewski, Letícia Sanguinetti; Martins, Dayane Santos; Hasse-Sousa, Mathias; Reckziegel, Ramiro; Lapa, Clara; Petry-Perin, Carolina; Britto, Maria Julia; Remus, Isadora Bosini; Gama, Clarissa Severino

doi:10.1080/13546805.2022.2133694

Cited by 3 publications

(1 citation statement)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparing pre- and post-treatment cognitive performance allows us to assess the impact of the treatment on cognitive function and gain insights into its potential benefits. While individual studies may focus on the specific effects of treatment on cognitive performance [ 31 ], a comprehensive understanding of the changes in cognitive abilities before and after treatment is essential. Therefore, in this study, we aim to fill this gap by comparing cognitive performance before and after treatment to provide valuable insights into the effectiveness of the treatment on cognitive function.…”

Section: Introductionmentioning

confidence: 99%

Comparison of cognitive performance in first-episode drug-naïve schizophrenia, bipolar II disorder, and major depressive disorder patients after treatment

Tang,

Huang,

Tan

et al. 2024

BMC Psychiatry

View full text Add to dashboard Cite

Background Cognitive impairment is a recognized fundamental deficit in individuals diagnosed with schizophrenia (SZ), bipolar II disorder (BD II), and major depressive disorder (MDD), among other psychiatric disorders. However, limited research has compared cognitive function among first-episode drug-naïve individuals with SZ, BD II, or MDD. Methods This study aimed to address this gap by assessing the cognitive performance of 235 participants (40 healthy controls, 58 SZ patients, 72 BD II patients, and 65 MDD patients) using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) before and after 12 weeks of treatment in SZ, BD II, and MDD patients. To clarify, the healthy controls only underwent RBANS testing at baseline, whereas the patient groups were assessed before and after treatment. The severity of symptoms in SZ patients was measured using the Positive and Negative Syndrome Scale (PANSS), and depression in BD II and MDD patients was assessed using the Hamilton Depression Scale-24 items (HAMD-24 items). Results Two hundred participants completed the 12-week treatment period, with 35 participants dropping out due to various reasons. This group included 49 SZ patients, 58 BD II patients, and 53 MDD patients. Among SZ patients, significant improvements in immediate and delayed memory were observed after 12 weeks of treatment compared to their initial scores. Similarly, BD II patients showed significant improvement in immediate and delayed memory following treatment. However, there were no significant differences in RBANS scores for MDD patients after 12 weeks of treatment. Conclusions In conclusion, the findings of this study suggest that individuals with BD II and SZ may share similar deficits in cognitive domains. It is important to note that standardized clinical treatment may have varying degrees of effectiveness in improving cognitive function in patients with BD II and SZ, which could potentially alleviate cognitive dysfunction.

show abstract

Section: Introductionmentioning

confidence: 99%